Abstract:Abstract Background Recent therapeutic advances and screening technologies have improved survival among patients with lung cancer, who are now at high risk of developing second primary lung cancer (SPLC). Recently, an SPLC risk‐prediction model (called SPLC‐RAT) was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking. The predictive performance of SPLC‐RAT was evaluated in a hospital‐based cohort of lung cancer survivors. Methods The authors analyzed data from 8448 ever‐smoking patients diagnosed with initial primary lung cancer (IPLC) in 1997–2006 at Mayo Clinic, with each patient followed for SPLC through 2018. The predictive performance of SPLC‐RAT and further explored the potential of improving SPLC detection through risk model‐based surveillance using SPLC‐RA T versus existing clinical surveillance guidelines. Results Of 8448 IPLC patients, 483 (5.7%) developed SPLC over 26,470 person‐years. The application of SPLC‐RAT showed high discrimination area under the receiver operating characteristics curve: 0.81). When the cohort was stratified by a 10‐year risk threshold of ≥5.6% (i.e., 80th percentile from the SPLC‐RAT development cohort), the observed SPLC incidence was significantly elevated in the high‐risk versus low‐risk subgroup (13.1% vs. 1.1%, p < 1 × 10 –6 ). The risk‐based surveillance through SPLC‐RAT (≥5.6% threshold) outperformed the National Comprehensive Cancer Network guidelines with higher sensitivity (86.4% vs. 79.4%) and specificity (38.9% vs. 30.4%) and required 20% fewer computed tomography follow‐ups needed to detect one SPLC (162 vs. 202). Conclusion In a large, hospital‐based cohort, the authors validated the predictive performance of SPLC‐RAT in identifying high‐risk survivors of SPLC and showed its potential to improve SPLC detection through risk‐based surveillance. Plain Language Summary Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC). However, no evidence‐based guidelines for SPLC surveillance are available for lung cancer survivors. Recently, an SPLC risk‐prediction model was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking. Using a large, real‐world cohort of lung cancer survivors, we showed the high predictive accuracy and risk‐stratification ability of the SPLC risk‐prediction model. Furthermore, we demonstrated the potential to enhance efficiency in detecting SPLC using risk model‐based surveillance strategies compared to the existing consensus‐based clinical guidelines, including the National Comprehensive Cancer Network.

Risk-based screening for second primary extrapulmonary malignancies in stage I lung cancer patients: a study based on SEER database

Risk of Second Primary Cancers among Long-Term Survivors of Breast Cancer

Second Primary Malignancy among Malignant Solid Tumor Survivors Aged 85 Years and Older

Life-long Follow-Up of Second Primary Lung and Extra-Pulmonary Cancer in Lung Cancer Patients is Needed

Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study

Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

Prognostic analysis of lung squamous cell carcinoma patients with second primary malignancies: a SEER database study

Second Primary Malignancies in Patients With Hepatocellular Carcinoma: A Population-Based Analysis

Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study

Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy

Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis

Analysis of Prognosis and Treatment Decisions for Patients with Second Primary Lung Cancer Following Esophageal Cancer

The Incidence of Second Primary Cancer in Male and Female Patients with Initial Colorectal Cancer: a SEER Population-Based Study.

Excessive Risk of Second Primary Cancers in Young‐onset Colorectal Cancer Survivors

The risk and latency evaluation of secondary primary malignancies of cervical cancer patients who received radiotherapy: A study based on the SEER database

Analyzing risk factors for second malignancies in early gastric carcinoma from the SEER database

Association Between Radiotherapy and Risk of Second Primary Malignancies in Patients with Resectable Lung Cancer: a Population-Based Study

Incidence and associated factors of developing second pelvic malignant neoplasms among prostate cancer patients treated with radiotherapy

Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer

Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model

Nomograms constructed for predicting diagnosis and prognosis in cervical cancer patients with second primary malignancies: a SEER database analysis